BACKGROUND: Recent studies suggested that anti-Saccharomyces cerevisiae antibody (ASCA) status was associated with diagnostic findings, stratified classification phenotypes, disease activity and clinical course of Crohn's disease (CD). However, the relationship between ASCA status and phenotypes of CD remains controversial in these studies. AIMS: The purpose of this study was to evaluate whether ASCA status is associated with the phenotypes and the risk of surgery in diverse populations in CD. METHODS: We conducted a meta-analysis of studies assessing the association of ASCA status with phenotypes and risk of surgery in CD. Three independent reviewers undertook data extraction. We pooled odds ratios separately for the cohort and case-control studies. RESULTS: We identified ten cohort studies (n = 2,365) and 14 case-control studies (n = 1,887) that investigated the association of ASCA status with phenotypes and risk of surgery in CD. The meta-analysis of the cohort studies showed significant association between the ASCA-positive status and higher risk of early-onset age (OR 2.25, 95 % CI 1.41-3.57, P < 0.001), ileal involvement disease (1.70, 1.05-2.77, P = 0.03), complicated disease behavior (2.09, 1.71-2.57, P < 0.001), perianal disease (1.49, 1.14-1.94, P = 0.004), and risk for surgery (1.61, 1.29-2.01, P < 0.001). Meta-analysis of the case-control studies also showed a significantly higher risk in ileal involvement disease (1.77, 1.25-2.49, P = 0.001), complicated disease behavior (2.13, 1.70-2.68, P < 0.001), perianal disease (1.96, 1.38-2.78, P < 0.001), and risk for surgery (1.71, 1.17-2.49, P = 0.005), except for the early-onset age (1.16, 0.80-1.69, P = 0.44). CONCLUSIONS: This meta-analysis indicated that positive ASCA status is a risk factor for early-onset age, ileal involvement, complicated behavior, perianal disease and requirement for surgery in CD.
BACKGROUND: Recent studies suggested that anti-Saccharomyces cerevisiae antibody (ASCA) status was associated with diagnostic findings, stratified classification phenotypes, disease activity and clinical course of Crohn's disease (CD). However, the relationship between ASCA status and phenotypes of CD remains controversial in these studies. AIMS: The purpose of this study was to evaluate whether ASCA status is associated with the phenotypes and the risk of surgery in diverse populations in CD. METHODS: We conducted a meta-analysis of studies assessing the association of ASCA status with phenotypes and risk of surgery in CD. Three independent reviewers undertook data extraction. We pooled odds ratios separately for the cohort and case-control studies. RESULTS: We identified ten cohort studies (n = 2,365) and 14 case-control studies (n = 1,887) that investigated the association of ASCA status with phenotypes and risk of surgery in CD. The meta-analysis of the cohort studies showed significant association between the ASCA-positive status and higher risk of early-onset age (OR 2.25, 95 % CI 1.41-3.57, P < 0.001), ileal involvement disease (1.70, 1.05-2.77, P = 0.03), complicated disease behavior (2.09, 1.71-2.57, P < 0.001), perianal disease (1.49, 1.14-1.94, P = 0.004), and risk for surgery (1.61, 1.29-2.01, P < 0.001). Meta-analysis of the case-control studies also showed a significantly higher risk in ileal involvement disease (1.77, 1.25-2.49, P = 0.001), complicated disease behavior (2.13, 1.70-2.68, P < 0.001), perianal disease (1.96, 1.38-2.78, P < 0.001), and risk for surgery (1.71, 1.17-2.49, P = 0.005), except for the early-onset age (1.16, 0.80-1.69, P = 0.44). CONCLUSIONS: This meta-analysis indicated that positive ASCA status is a risk factor for early-onset age, ileal involvement, complicated behavior, perianal disease and requirement for surgery in CD.
Authors: R K Linskens; R C Mallant-Hent; L S Murillo; B M E von Blomberg; B Z Alizadeh; A S Peña Journal: Dig Liver Dis Date: 2004-01 Impact factor: 4.088
Authors: J Halfvarson; A Standaert-Vitse; G Järnerot; B Sendid; T Jouault; L Bodin; A Duhamel; J F Colombel; C Tysk; D Poulain Journal: Gut Date: 2005-04-29 Impact factor: 23.059
Authors: Marla C Dubinsky; Ying-Chao Lin; Debra Dutridge; Yoana Picornell; Carol J Landers; Sharmayne Farrior; Iwona Wrobel; Antonio Quiros; Eric A Vasiliauskas; Bruce Grill; David Israel; Ron Bahar; Dennis Christie; Ghassan Wahbeh; Gary Silber; Saied Dallazadeh; Praful Shah; Danny Thomas; Drew Kelts; Robert M Hershberg; Charles O Elson; Stephan R Targan; Kent D Taylor; Jerome I Rotter; Huiying Yang Journal: Am J Gastroenterol Date: 2006-02 Impact factor: 10.864
Authors: V Annese; A Piepoli; F Perri; G Lombardi; A Latiano; G Napolitano; G Corritore; P Vandewalle; D Poulain; J F Colombel; A Andriulli Journal: Aliment Pharmacol Ther Date: 2004-11-15 Impact factor: 8.171
Authors: B Sendid; J F Colombel; P M Jacquinot; C Faille; J Fruit; A Cortot; D Lucidarme; D Camus; D Poulain Journal: Clin Diagn Lab Immunol Date: 1996-03
Authors: S Desplat-Jégo; C Johanet; A Escande; J Goetz; N Fabien; N Olsson; E Ballot; J Sarles; J J Baudon; J C Grimaud; M Veyrac; P Chamouard; R L Humbel Journal: World J Gastroenterol Date: 2007-04-28 Impact factor: 5.742
Authors: Alain M Schoepfer; Thomas Schaffer; Stefan Mueller; Beatrice Flogerzi; Erik Vassella; Beatrice Seibold-Schmid; Frank Seibold Journal: Inflamm Bowel Dis Date: 2009-09 Impact factor: 5.325
Authors: Paolo Giuffrida; Massimo Pinzani; Gino R Corazza; Antonio Di Sabatino Journal: United European Gastroenterol J Date: 2016-03-21 Impact factor: 4.623
Authors: Ali Erkan Duman; Sadettin Hülagü; Altay Çelebi; Uğur Korkmaz; Mahmut Mert Musul; Ömer Şentürk; Göktuğ Şirin; Hasan Yılmaz; Deniz Öğütmen Koç; Gökhan Dindar; Murat Öztürkler; Neslihan Bozkurt; Hale Maral Kır Journal: Turk J Gastroenterol Date: 2019-01 Impact factor: 1.852
Authors: Hester Eppinga; H Bing Thio; Marco W J Schreurs; Blerdi Blakaj; Ruena I Tahitu; Sergey R Konstantinov; Maikel P Peppelenbosch; Gwenny M Fuhler Journal: PLoS One Date: 2017-05-09 Impact factor: 3.240
Authors: Joana Torres; Flavio Caprioli; Konstantinos H Katsanos; Triana Lobatón; Dejan Micic; Marco Zerôncio; Gert Van Assche; James C Lee; James O Lindsay; David T Rubin; Remo Panaccione; Jean-Frédéric Colombel Journal: J Crohns Colitis Date: 2016-06-09 Impact factor: 9.071